

## COVID-19 Vaccine: A Tool for Practitioners to Determine and Document Patient Eligibility for the AstraZeneca/COVISHIELD Vaccine

This (optional) tool has been developed to assist pharmacists and physicians with determining and documenting patient eligibility for the AstraZeneca/COVISHIELD vaccine. Pharmacists and physicians are expected to work through Priority 1 conditions in their patient population before moving to Priority 2 individuals however, this does not replace clinical judgement concerning the practitioner's assessment of the patient's risk. Eligibility criteria is subject to frequent change. Check the website: [www.manitoba.ca/covid19/vaccine/eligibility-criteria.html](http://www.manitoba.ca/covid19/vaccine/eligibility-criteria.html) for up-to-date eligibility criteria. Check the criteria/condition(s) that apply.

### Priority 1:

- Persons aged 50 to ≤ 64 years of age in the general population **OR** First Nation people aged 30 to ≤ 64 years, with one or more of the following conditions:
  - end stage renal disease undergoing hemodialysis **OR** peritoneal dialysis
  - cirrhosis due to any cause **OR** portal hypertension
  - heart failure (class III/IV ), ventricular assist device **OR** adult congenital heart disease stage C and D
  - severe COPD, pulmonary hypertension, pulmonary fibrosis, interstitial lung disease **OR** cystic fibrosis
  - history of cerebral vascular accident with residual deficits
  - malignant hematologic disorders including leukemia and lymphoma **OR** clonal blood disorder
  - malignant neoplasms (solid tissue) who will receive or are currently receiving immunosuppressive therapy including chemotherapy
  - severe obesity (BMI ≥ 40)
  - receiving one or more of the following immunosuppressive therapies: B cell therapies (e.g., rituximab, ocrelizumab), cyclophosphamide, alemtuzumab, calcineurin inhibitors, chronic dose prednisone ≥20mg/day, mycophenolate, sulfasalazine and JAK inhibitors (e.g., tofacitinib)
  - solid organ or hematopoietic stem cell transplant (candidate or recipient)
  - trisomy 21 (Down's syndrome)
  - asplenia or hyposplenism (including sickle cell disease)
  - receiving home care ≥ 4 times/week **OR** receiving 24/7 support from Community Living Disability Services
- Pregnant individuals aged 18 to ≤ 64 years with one of: aged ≥ 35 years, BMI ≥ 30, pre-existing diabetes, pre-existing hypertension, cardiac or pulmonary disease.
- Persons aged 18 to ≤ 64 years of age who are already eligible, but have not yet received a dose of mRNA vaccine (Pfizer-BioNTech or Moderna), as per the following:
 

---
- Or as reasonably determined per the patients individual risk assessment: \_\_\_\_\_

**Priority 2:**

- Persons aged 50 to ≤ 64 years of age in the general population **OR** First Nation people aged 30 to ≤ 64 years, with one or more of the following conditions:
  - Chronic cardiovascular disease including heart failure (class I/II), coronary artery disease, malignant tachyarrhythmia **OR** cardiomyopathies
  - chronic liver disease
  - chronic neurologic **OR** neurodevelopmental conditions including cerebral palsy, Parkinson's disease, multiple sclerosis, ALS **OR** dementia (including Alzheimer's disease)
  - chronic pulmonary disease including COPD **OR** severe and/or uncontrolled asthma
  - chronic renal disease
  - HIV (CD4 cell count ≥ 200 x 10<sup>6</sup>/L and CD4 percentage ≥ 15%)
  - severe systemic autoimmune disorders (e.g., systemic lupus erythematosus, scleroderma, myocarditis, rheumatoid arthritis)
  - type 1 or 2 diabetes mellitus (poorly controlled and/or with complications)
  - active tuberculosis (current or previous) **OR** current latent tuberculosis (LTBI)
  - receiving [immunosuppressing therapy](#)<sup>1</sup>
  - receiving homecare ≤ 3 times/week **OR** any level of Community Living Disability Services supports (or as per family physician determination of equivalent levels of family support)
  - household contacts of individuals with Priority 1 chronic health conditions **OR** designated support person(s) for personal care home residents (in the authorized age category)

---

<sup>1</sup> See the Canadian Immunization Guide: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html#a25>